CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $238.54M, lower than 95% of all stocks globally
- PositionCurrent ratio is 0.35×, lower than 95% of its Biotechnology peers (median 5.64×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.87BHKD238.54M · vs all stocks (USD)
Revenue (TTM)
0.00HKDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.1210xvs all stocks
52-Week Change
-91.86%vs all stocks
Market Capitalization
1.87BHKD238.54M · vs all stocks (USD)
Enterprise Value
608.78MHKD77.61M · vs all stocks (USD)
Enterprise to EBITDA
-4.30xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-18.75%vs Biotechnology peers
Revenue (TTM)
0.00HKDvs all stocks (USD)
Revenue per Share (TTM)
0.00HKDUpdated Aug 21, 2026Gross Profit (TTM)
0.00HKDvs all stocks (USD)
EBITDA (TTM)
-141.48MHKD-18.04M · vs all stocks (USD)
Net Income (TTM)
-268.51MHKD-34.23M · vs all stocks (USD)
Operating Cash Flow (TTM)
-113.20MHKD-14.43M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-77.14MHKD-9.83M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-3.28MCNYFY2025 · Dec 31, 2025Revenue
0.00CNYFY2025 · Dec 31, 2025Operating Income
-155.80MCNY-23.17M · vs all stocks (USD)
Pre-tax Income
-230.91MCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
-230.91MCNYFY2025 · Dec 31, 2025EBIT
-224.10MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-168.96MCNYFY2025 · Dec 31, 2025Research & Development
132.82MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
41.04MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
532.00KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
6.81MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.4200CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.4200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
549.00MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
549.00MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-230.91MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
122.00KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-233.44MCNYFY2025 · Dec 31, 2025Free Cash Flow
-247.48MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
54.46MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-230.91MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-2.85MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
351.00KCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-27.00KCNYFY2025 · Dec 31, 2025Capital Expenditures
-14.05MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-568.00KCNYFY2025 · Dec 31, 2025Purchase of Investments
-120.00MCNYFY2025 · Dec 31, 2025Sale of Investments
30.62MCNYFY2025 · Dec 31, 2025Other Investing Activity
5.58MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-97.85MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
44.91MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-44.91MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
234.64MCNYFY2025 · Dec 31, 2025Shares Outstanding
617.50MSharesUpdated Aug 21, 2026Float Shares
216.11MSharesUpdated Aug 21, 2026% Held by Insiders
71.69%vs all stocks
% Held by Institutions
6.39%vs all stocks
Total Cash (MRQ)
179.83MHKD22.93M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2500HKDUpdated Aug 21, 2026Total Debt (MRQ)
512.23MHKD65.30M · vs all stocks (USD)
Current Ratio (MRQ)
0.3500xvs Biotechnology peers
Book Value per Share (MRQ)
-0.0268HKDUpdated Aug 21, 2026Total Assets
602.94MCNY89.66M · vs all stocks (USD)
Total Current Assets
171.59MCNYFY2025 · Dec 31, 2025Total Liabilities
620.14MCNYFY2025 · Dec 31, 2025Total Non-current Assets
431.35MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
129.29MCNYFY2025 · Dec 31, 2025Total Current Liabilities
490.85MCNYFY2025 · Dec 31, 2025Cash
54.46MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
54.46MCNYFY2025 · Dec 31, 2025Other Short-term Investments
100.11MCNYFY2025 · Dec 31, 2025Inventory
4.52MCNYFY2025 · Dec 31, 2025Accounts Payable
35.23MCNYFY2025 · Dec 31, 2025Short-term Debt
362.47MCNYFY2025 · Dec 31, 2025Long-term Debt
77.79MCNYFY2025 · Dec 31, 2025Common Stock (Book)
4.31MCNYFY2025 · Dec 31, 2025Retained Earnings
-2.04BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
-17.21MCNY-2.56M · vs all stocks (USD)
52-Week Low
0.3300HKDUpdated Aug 21, 202652-Week High
5.83HKDUpdated Aug 21, 202652-Week Change
-91.86%vs all stocks
Beta
0.1210xvs all stocks
50-Day MA
0.4904HKDUpdated Aug 21, 2026200-Day MA
1.99HKDUpdated Aug 21, 2026Avg 10-Day Volume
132.40KSharesUpdated Aug 21, 2026Avg 30-Day Volume
304.95KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.4900HKDUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.35×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.35Industry median: 5.64Industry P5: 1.06Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $238.54M, lower than 95% of all stocks globallySignificant
Market cap (USD): 238,537,286.158Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Shenqi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fulcrum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Heartseed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Protara Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule